Delcath Systems (DCTH) reported Thursday preliminary Q3 revenue of $11.2 million that includes $10 million in US revenue from the commercialization of Hepzato Kit, which is indicated for treating metastatic uveal melanoma.
The oncology company reported $434,000 in Q3 revenue a year earlier.
Analysts polled by Capital IQ expect Q3 revenue of $9.5 million.
The company said the $10 million in US revenue triggers a $25 million financing tranche relating to warrants issued in March 2023. Warrant holders will have 21 days to exercise their warrants to acquire common shares at a price of $6 apiece for an aggregate exercise price of up to about $25 million, the company said.
Delcath Chief Executive Gerard Michel said the additional $25 million of financing will be used to support an ongoing commercial launch and invest in new clinical trials to expand indications that the company intends to start next year.
The company is scheduled to report Q3 financial results on Nov. 8.
Delcath shares were up almost 14% in early trading Thursday.
Price: 10.83, Change: +1.32, Percent Change: +13.83
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。